StudyFinder

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

RECRUITING
I'm interested

40 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:
\- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verification of usual interstitial pneumonia(UIP) or probable UIP.
Exclusion Criteria:
* History of stroke within 6 months prior to screening * In the opinion of the investigator, other clinically significant pulmonary abnormalities * History of any malignancy up to 5 years prior screening visit, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix.

DRUG: ABBV-142, DRUG: Placebo for ABBV-142

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

ABBVIE CALL CENTER - abbvieclinicaltrials@abbvie.com
NCT07230288

Back